Ascendis Pharma (ASND) director William Fairey reports equity and RSU holdings

Rhea-AI Filing Summary

Ascendis Pharma A/S director William Fairey has filed an initial ownership report outlining his equity position in the company. The filing shows direct ownership of 2,117 Ordinary Shares, as well as warrants over 9,160 Ordinary Shares with an exercise price of $102.7000 per share that expire on September 13, 2032.

He also holds several grants of Restricted Stock Units representing 1,374, 2,070 and 1,930 underlying Ordinary Shares. Each restricted stock unit represents a contingent right to receive one American Depositary Share, and each ADS represents one Ordinary Share. The footnotes state that these RSUs vest on or beginning on March 1, 2027 under different installment schedules.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Fairey William

(Last) (First) (Middle)

C/O ASCENDIS PHARMA A/S

TUBORG BOULEVARD 12

(Street)

HELLERUP DK-2900

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Ascendis Pharma A/S [ ASND ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares(1)	2,117	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrants	(2)	09/13/2032	Ordinary Shares	9,160	$102.7	D
Restricted Stock Units	(3)	(3)	Ordinary Shares	1,374	(4)	D
Restricted Stock Units	(5)	(5)	Ordinary Shares	2,070	(4)	D
Restricted Stock Units	(6)	(6)	Ordinary Shares	1,930	(4)	D

Explanation of Responses:

1. Includes American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share.

2. The warrants vested 25% on September 13, 2023 and thereafter in 36 equal monthly installments.

3. The restricted stock units vest on March 1, 2027 and have no expiration date.

4. Each restricted stock unit represents a contingent right to receive one ADS.

5. The restricted stock units vest in two equal annual installments beginning on March 1, 2027.

6. The restricted stock units vest in three equal annual installments beginning on March 1, 2027.

	/s/ Michael Wolff Jensen as attorney-in-fact for William Fairey	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Ascendis Pharma (ASND) director William Fairey report owning in this Form 3?

He reports 2,117 directly held Ordinary Shares plus derivative interests. These include warrants over 9,160 Ordinary Shares and multiple Restricted Stock Unit awards linked to additional Ordinary Shares through American Depositary Shares, all detailed as of the Form 3 reporting date.

How many Ascendis Pharma (ASND) warrants does William Fairey report on his Form 3?

He reports warrants over 9,160 underlying Ordinary Shares. These warrants carry an exercise price of $102.7000 per share and expire on September 13, 2032, providing long-dated potential exposure to Ascendis Pharma’s equity if exercised in the future.

What Restricted Stock Units does William Fairey hold in Ascendis Pharma (ASND)?

He holds several RSU awards covering 1,374, 2,070 and 1,930 underlying Ordinary Shares. Each unit is a contingent right to receive one American Depositary Share, with the awards vesting on or beginning on March 1, 2027 according to different installment schedules.

When do William Fairey’s Ascendis Pharma (ASND) Restricted Stock Units vest?

One RSU grant vests in full on March 1, 2027. Other RSU awards vest in two or three equal annual installments beginning on March 1, 2027, as specified in the footnotes describing the vesting schedules and duration.

What is the relationship between Ascendis Pharma (ASND) ADSs and Ordinary Shares in this Form 3?

Each American Depositary Share represents one Ordinary Share of Ascendis Pharma. The filing notes that each Restricted Stock Unit corresponds to a contingent right to receive one ADS, effectively linking RSU awards to the same economic interest as one Ordinary Share.

Does this Ascendis Pharma (ASND) Form 3 show any insider buying or selling by William Fairey?

The Form 3 functions as an initial ownership report and lists existing holdings rather than new trades. The transactions are categorized as holdings with unknown transaction codes, and summary data show no reported buys, sells, gifts, or tax-withholding events.